James Berenson, MD
Hematology-Oncology · West Hollywood, CANPI 1124051560
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $807,255 of the $1,013,393 with a category attached, or 79.7%. 34 manufacturers reported payments, led by Sanofi at 25.6% of the total. Reporting peaked in 2019 at $348,249 and has fallen 85.7% since, to $49,921 in 2025. Among hematology-oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,051 payments — averaging $964.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$259K
- Karyopharm Therapeutics Inc.$185K
- E.r. Squibb & Sons, L.L.C.$160K
- Johnson & Johnson$143K
- Amgen$85K
- Takeda Pharmaceuticals U.S.A., Inc.$77K
- plus $105K from 28 others
Across 251 payments — averaging $29,793 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$2.6M
- Takeda Pharmaceuticals U.S.A., Inc.$1.4M
- Sanofi$878K
- AbbVie$865K
- Karyopharm Therapeutics Inc.$521K
- Bristol Myers Squibb$426K
- plus $706K from 5 others
What the payments were for
- Consulting fees$91,7379%
- Speaking & faculty fees$807,25580%
- Travel & lodging$88,5109%
- Food & beverage$25,0572%
- Education$8340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 205 | $258,996 |
| Karyopharm Therapeutics Inc. | 164 | $184,928 |
| E.r. Squibb & Sons, L.L.C. | 131 | $160,206 |
| Johnson & Johnson | 188 | $143,408 |
| Amgen | 65 | $84,503 |
| Takeda Pharmaceuticals U.S.A., Inc. | 95 | $76,582 |
| Bristol Myers Squibb(2 entities) | 49 | $39,214 |
| AMAG Pharmaceuticals, Inc. | 27 | $25,990 |
| GSK | 25 | $19,083 |
| Daiichi Sankyo Inc. | 3 | $4,554 |
| Merck | 7 | $3,800 |
| AbbVie | 3 | $3,420 |
| Pfizer | 22 | $2,775 |
| Verastem, Inc. | 1 | $1,725 |
| Aadi Bioscience, Inc. | 2 | $1,700 |
| Janssen Scientific Affairs, LLC | 10 | $531 |
| Incyte Corporation | 13 | $517 |
| Sanofi-aventis U.S. LLC | 4 | $297 |
| Sebia Inc | 2 | $153 |
| Regeneron Healthcare Solutions, Inc. | 4 | $146 |
| EUSA Pharma (US) LLC | 2 | $144 |
| Teva Pharmaceuticals USA, Inc. | 5 | $113 |
| Secura Bio, Inc. | 8 | $94 |
| Legend Biotech USA Inc. | 3 | $90 |
| AstraZeneca | 3 | $73 |
| American Regent | 1 | $70 |
| Epizyme, Inc. | 1 | $45 |
| Regeneron | 1 | $45 |
| Cardinal Health 108 LLC | 1 | $42 |
| Beigene USA, Inc. | 2 | $40 |
| Gilead | 1 | $34 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Heron Therapeutics, Inc. | 1 | $24 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,013,393 in reported general payments places this provider in the 95th percentile of 53 hematology-oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SarclisaIsatuximab-Irfc | 291 | $2,336,543 |
| PomalystPomalidomide | 97 | $2,157,527 |
| RevlimidLenalidomide | 92 | $1,619,964 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 74 | $1,228,893 |
| EmplicitiElotuzumab | 76 | $891,038 |
| Lenalidomide | 65 | $883,478 |
| KyprolisCarfilzomib | 53 | $717,744 |
| XgevaDenosumab | 106 | $332,097 |
| DarzalexDaratumumab | 25 | $185,880 |
| NinlaroIxazomib Citrate | 11 | $145,565 |
| VenclextaVenetoclax | 12 | $105,030 |
| ProcritEpoetin Alfa | 15 | $61,638 |
| Acyclovir | 281 | $6,908 |
| Methylprednisolone | 254 | $6,710 |
| PrevaliteCholestyramine | 19 | $1,638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Empliciti | $160,206 | $3,048,565173 claims |
| SanofiSarclisa | $258,996 | $2,336,543291 claims |
| Bristol Myers SquibbRevlimid | $39,214 | $1,619,96492 claims |
| AmgenKyprolis, Xgeva | $84,503 | $1,049,841159 claims |
| Johnson & JohnsonDarzalex, Procrit | $143,408 | $247,51840 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $76,582 | $145,56511 claims |
| AbbVieVenclexta | $3,420 | $105,03012 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $113 | $6,908281 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 53 hematology-oncology providers in California.
Other hematology-oncology in West Hollywood
- Levon QasabianWest Hollywood$415
- Ari BaronSan Francisco$705K
- Jeffrey WolfSan Francisco$407K
- Haresh JhangianiFountain Valley$77K
- Mark ScholzMarina del Rey$62K
- Derrick SuFountain Valley$53K
- Peyman Salimi-TariFountain Valley$49K
- Janet PanFountain Valley$46K
- Bertrand TuanSan Francisco$45K
- Brian ChoiRiverside$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.